[go: up one dir, main page]

CY1123844T1 - Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης - Google Patents

Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης

Info

Publication number
CY1123844T1
CY1123844T1 CY20211100017T CY211100017T CY1123844T1 CY 1123844 T1 CY1123844 T1 CY 1123844T1 CY 20211100017 T CY20211100017 T CY 20211100017T CY 211100017 T CY211100017 T CY 211100017T CY 1123844 T1 CY1123844 T1 CY 1123844T1
Authority
CY
Cyprus
Prior art keywords
lysosomic
pharmaceutical compositions
storage disorders
uses addressing
addressing
Prior art date
Application number
CY20211100017T
Other languages
English (en)
Inventor
Michael Strupp
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59859423&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1123844(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1613828.1A external-priority patent/GB201613828D0/en
Priority claimed from GBGB1702552.9A external-priority patent/GB201702552D0/en
Priority claimed from GBGB1705762.1A external-priority patent/GB201705762D0/en
Priority claimed from GBGB1706854.5A external-priority patent/GB201706854D0/en
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of CY1123844T1 publication Critical patent/CY1123844T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα αποκάλυψη προβλέπει αγωγή διαταραχών λυσοσωμιακής αποθήκευσης (LSDs) περιλαμβάνοντας χορήγηση ακετυλ-λευκίνης ή ενός φαρμακευτικός αποδεκτού άλατος εξ αυτής.
CY20211100017T 2016-08-11 2021-01-12 Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης CY1123844T1 (el)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB1613828.1A GB201613828D0 (en) 2016-08-11 2016-08-11 Therapeutic agents for lysosomal storage disorders
GBGB1702552.9A GB201702552D0 (en) 2017-02-16 2017-02-16 Therapeutic agents for lysosomal storage disorders
GBGB1705762.1A GB201705762D0 (en) 2017-04-10 2017-04-10 Therapeutic agents for lysosomal storage disorders
GBGB1706854.5A GB201706854D0 (en) 2017-04-28 2017-04-28 Therapeutic agents for lysosomal storage disorders
EP17767933.9A EP3359146B1 (en) 2016-08-11 2017-08-11 Pharmaceutical compositions and uses directed to lysosomal storage disorders
PCT/IB2017/054928 WO2018029657A1 (en) 2016-08-11 2017-08-11 Pharmaceutical compositions and uses directed to lysosomal storage disorders

Publications (1)

Publication Number Publication Date
CY1123844T1 true CY1123844T1 (el) 2022-05-27

Family

ID=59859423

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20191100279T CY1121345T1 (el) 2016-08-11 2019-03-08 Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης
CY20211100017T CY1123844T1 (el) 2016-08-11 2021-01-12 Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20191100279T CY1121345T1 (el) 2016-08-11 2019-03-08 Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης

Country Status (28)

Country Link
US (3) US11400067B2 (el)
EP (4) EP4342461A3 (el)
JP (3) JP7393943B2 (el)
KR (4) KR102412724B1 (el)
CN (1) CN109843275A (el)
AU (3) AU2017308864B2 (el)
CA (1) CA3033557A1 (el)
CY (2) CY1121345T1 (el)
DK (2) DK3482754T3 (el)
ES (2) ES2716133T3 (el)
HK (1) HK1253282B (el)
HR (2) HRP20190344T1 (el)
HU (2) HUE041914T2 (el)
IL (2) IL264610B2 (el)
LT (2) LT3482754T (el)
MA (2) MA43876B1 (el)
MD (2) MD3359146T2 (el)
ME (1) ME03340B (el)
MX (2) MX384447B (el)
PL (2) PL3482754T3 (el)
PT (2) PT3482754T (el)
RS (2) RS61442B1 (el)
RU (1) RU2749515C2 (el)
SG (1) SG11201901048VA (el)
SI (2) SI3359146T1 (el)
SM (2) SMT201900154T1 (el)
TN (1) TN2019000032A1 (el)
WO (1) WO2018029657A1 (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3359146T1 (sl) 2016-08-11 2019-05-31 Intrabio Ltd Farmacevtski sestavki in uporabe, usmerjene na motnje lisosomalnega skladiščenja
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
US12145899B2 (en) * 2018-12-06 2024-11-19 Intrabio Ltd. Deuterated analogs of acetyl-leucine
KR20210135272A (ko) 2019-03-02 2021-11-12 인트라바이오 리미티드 질환을 치료하기 위한 류신, 아세틸 류신, 및 관련된 유사체
PT3989962T (pt) 2019-06-28 2025-10-09 Intrabio Ltd Terapia de combinação com acetil-leucina e miglustato para tratamento de uma doença de armazenamento lisossómico
WO2022264037A1 (en) * 2021-06-14 2022-12-22 Intrabio Ltd. Branched-chain amino acid derivatives to treat disease

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2749512B1 (fr) * 1996-06-10 1999-08-13 Pf Medicament Utilisation de l'acetyl dl leucine pour le traitement des tremblements
WO2001097829A2 (en) * 2000-06-19 2001-12-27 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
FR2883180B1 (fr) 2005-03-18 2007-05-25 Pierre Fabre Medicament Sa Utilisation de l'acetyl-leucine pour la preparation d'un medicament destine au traitement de troubles de l'equilibre
FR2905600B1 (fr) 2006-09-13 2010-01-15 Pf Medicament Traitement des vertiges par l'acetyl-l-leucine.
WO2009114729A2 (en) * 2008-03-14 2009-09-17 Irm Llc Compounds, compositions and methods for treating lysosomal storage diseases and disorders
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
TN2010000566A1 (en) 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
GB201114017D0 (en) * 2011-08-15 2011-09-28 Univ Dundee Inhibitors against endosomal/ysosomal enzymes
WO2013182652A1 (en) * 2012-06-06 2013-12-12 Fondazione Telethon Allosteric chaperones and uses thereof
KR102247701B1 (ko) 2016-02-26 2021-05-03 한미정밀화학주식회사 폴리에틸렌글리콜 디알데히드 유도체의 제조방법
SI3359146T1 (sl) 2016-08-11 2019-05-31 Intrabio Ltd Farmacevtski sestavki in uporabe, usmerjene na motnje lisosomalnega skladiščenja
CN109789114A (zh) 2016-08-11 2019-05-21 内在生物技术有限公司 神经退行性疾病的治疗剂

Also Published As

Publication number Publication date
HUE052837T2 (hu) 2021-05-28
RU2019106493A3 (el) 2020-10-26
HK1253282B (en) 2020-02-07
RS61442B1 (sr) 2021-03-31
SMT202100050T1 (it) 2021-03-15
JP7393943B2 (ja) 2023-12-07
HK1253282A1 (en) 2019-06-14
CA3033557A1 (en) 2018-02-15
SMT201900154T1 (it) 2019-05-10
ME03340B (me) 2019-10-20
TN2019000032A1 (en) 2020-07-15
MD3359146T2 (ro) 2019-04-30
ES2716133T3 (es) 2019-06-10
LT3359146T (lt) 2019-04-25
PT3359146T (pt) 2019-03-27
EP3482754B1 (en) 2020-12-23
KR102412724B1 (ko) 2022-06-23
MX384447B (es) 2025-03-14
JP2022050564A (ja) 2022-03-30
DK3482754T3 (da) 2021-02-01
WO2018029657A1 (en) 2018-02-15
PT3482754T (pt) 2021-02-03
PL3482754T3 (pl) 2021-07-05
AU2017308864B2 (en) 2023-06-01
MA55947A (fr) 2022-03-23
AU2023202903B2 (en) 2025-03-06
SG11201901048VA (en) 2019-03-28
SI3482754T1 (sl) 2021-04-30
LT3482754T (lt) 2021-05-10
IL314107A (en) 2024-09-01
EP3359146A1 (en) 2018-08-15
MD3482754T2 (ro) 2021-05-31
EP4342461A2 (en) 2024-03-27
US20190201359A1 (en) 2019-07-04
IL264610B2 (en) 2024-12-01
AU2023202903A1 (en) 2023-05-25
US20220331278A1 (en) 2022-10-20
EP4342461A3 (en) 2024-05-29
ES2849566T3 (es) 2021-08-19
RS58478B1 (sr) 2019-04-30
HRP20210153T1 (hr) 2021-05-28
US11400067B2 (en) 2022-08-02
CN109843275A (zh) 2019-06-04
KR102467953B1 (ko) 2022-11-16
AU2025203479A1 (en) 2025-05-29
HRP20190344T1 (hr) 2019-04-19
MA43876B1 (fr) 2019-04-30
SI3359146T1 (sl) 2019-05-31
EP3865126A1 (en) 2021-08-18
BR112019002719A2 (pt) 2019-05-14
JP2024059863A (ja) 2024-05-01
CY1121345T1 (el) 2020-05-29
KR20240110078A (ko) 2024-07-12
KR20220154849A (ko) 2022-11-22
MA43876A (fr) 2018-08-15
MX2021008432A (es) 2021-08-19
EP3359146B1 (en) 2019-01-23
IL264610A (en) 2019-02-28
DK3359146T3 (en) 2019-04-08
US12433862B2 (en) 2025-10-07
KR20190039226A (ko) 2019-04-10
AU2017308864A1 (en) 2019-02-21
JP7757446B2 (ja) 2025-10-21
PL3359146T3 (pl) 2019-07-31
KR20220044372A (ko) 2022-04-07
RU2019106493A (ru) 2020-09-11
RU2749515C2 (ru) 2021-06-11
HUE041914T2 (hu) 2019-06-28
JP2019524821A (ja) 2019-09-05
US12433863B2 (en) 2025-10-07
MX2019001577A (es) 2019-08-29
RU2021115932A (ru) 2021-06-08
EP3482754A1 (en) 2019-05-15
IL264610B1 (en) 2024-08-01
US20240197663A1 (en) 2024-06-20

Similar Documents

Publication Publication Date Title
CY1123844T1 (el) Φαρμακευτικες συνθεσεις και χρησεις που απευθυνονται σε διαταραχες λυσοσωμιακης αποθηκευσης
CY1125193T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν μελοξικαμη
CY1123571T1 (el) Βουπροπιονη για τη ρυθμιση των φαρμακευτικων επιπεδων δεξτρομεθορφανης στο πλασμα
CY1122966T1 (el) 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου
CY1122730T1 (el) 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
CY1121930T1 (el) Θεραπευτικοι παραγοντες για νευροεκφυλιστικες ασθενειες
CY1121849T1 (el) Μεθοδοι και συνθεσεις για τη θεραπεια του καρκινου
MX2016012262A (es) Cenicriviroc para el tratamiento de fibrosis.
MX378273B (es) Compuestos activos hacia bromodominios.
CY1125150T1 (el) Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
CY1123366T1 (el) Παραγωγα 8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δeκανιου
CY1124041T1 (el) Συνθεσεις που περιλαμβανουν κυκλοσπορινη
DOP2016000254A (es) Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso.
CY1122473T1 (el) Βελτιστοποιημενο μεσαλαζiνουχο δισκιο υψηλης δοσης
EP3672587A4 (en) PHARMACEUTICAL COMPOSITIONS INTENDED FOR THE TREATMENT OF OPHTHALMIC DISORDERS
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
EA201890457A1 (ru) Комбинации антитела против ox40 и модулятора tlr4 и их применение
CY1123408T1 (el) Φαρμακευτικες συνθεσεις και χρηση των αυτων
MX2017010277A (es) Cenicriviroc para el tratamiento de la fibrosis.
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
EA201700254A1 (ru) Комбинация
EA201501130A1 (ru) Офтальмологическая фармацевтическая композиция